The primary endpoint in this study is trough FEV1 response after 24 weeks. 24 weeks [clinicaltrials_resource:c99a142f37a2050a697b60a3e6d6983a]

The primary endpoint in this study is trough FEV1 response after 24 weeks. 24 weeks [clinicaltrials_resource:c99a142f37a2050a697b60a3e6d6983a]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:c99a142f37a2050a697b60a3e6d6983a
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. [clinicaltrials:NCT00528996]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary endpoint in this study is trough FEV1 response after 24 weeks. 24 weeks [clinicaltrials_resource:c99a142f37a2050a697b60a3e6d6983a]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:c99a142f37a2050a697b60a3e6d6983a
Bio2RDF identifier
c99a142f37a2050a697b60a3e6d6983a
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c99a142f37a2050a697b60a3e6d6983a
measure [clinicaltrials_vocabulary:measure]
The primary endpoint in this study is trough FEV1 response after 24 weeks.
time frame [clinicaltrials_vocabulary:time-frame]
identifier
clinicaltrials_resource:c99a142f37a2050a697b60a3e6d6983a
title
The primary endpoint in this study is trough FEV1 response after 24 weeks. 24 weeks
@en
inDataset
type
label
The primary endpoint in this s ...... a142f37a2050a697b60a3e6d6983a]
@en